Dicerna Pharmaceuticals Inc. | |
Stock Exchange | Frankfurt Stock Exchange |
EPS |
- |
Market Cap |
- |
Shares Outstanding |
52.97 M |
Public Float |
35.07 M |
Dicerna Pharmaceuticals Inc. | |
Stock Exchange | NASDAQ Stock Market |
EPS |
$1.7 |
Market Cap |
$1.01 B |
Shares Outstanding |
68.32 M |
Public Float |
45.19 M |
Address |
87 Cambridgepark Drive Cambridge Massachusetts 02140 United States |
Employees | - |
Website | http://www.dicerna.com |
Updated | 07/08/2019 |
Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery and development of treatments for rare diseases, chronic liver diseases, cardiovascular disease, and viral liver infectious diseases using its proprietary GalXC RNAi technology platform to build a pipeline in these therapeutic areas. The company was founded by Douglas M. Fambrough III, Mark A. |